Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease

Hai-Chen Lv,Hong-Yi Wu,Jia-Sheng Yin,Jun-Bo Ge
DOI: https://doi.org/10.18632/oncotarget.19450
2017-07-22
Oncotarget
Abstract:Platelet aggregation and inflammation are both implicated in coronary artery disease (CAD). Thrombin induced platelet-fibrin clot strength (MA<sub>Thrombin</sub>) measured by thrombelastography (TEG) has been proved to be a novel marker of platelet aggregation. The aim of this study was to investigate the correlation of MA<sub>Thrombin</sub> to platelet volume indices (PVIs) or to inflammatory markers in different types of CAD. 206 patients with different types of CAD were enrolled. MA<sub>Thrombin</sub>, PVIs, including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR) as well as inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fbg) were measured. Multiple linear regression models were used to analyze the association between MA<sub>Thrombin</sub>, PVIs, and inflammatory markers. MA<sub>Thrombin</sub> and inflammatory markers both varied with CAD types (P&lt;0.001). MA<sub>Thrombin</sub> was correlated to PVIs in NSTEMI individuals (MPV, r=0.393, P=0.007; PDW, r=0.334, P=0.023; P-LCR, r=0.382, P=0.008), but had inner-link with inflammatory markers in STEMI cases (hs-CRP, r=0.499, P&lt;0.001; Fbg, r=0.500, P&lt;0.001). These findings may suggest different mechanisms of platelet aggregation in different types of CAD. Moreover, MA<sub>Thrombin</sub> may be used as a potential parameter to evaluate platelet aggregation and inflammation together.
English Else
What problem does this paper attempt to address?